Dienifer Hermann Sirena
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dienifer Hermann Sirena has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Monique Maria Franco da Silva
Postgraduate Program in Physiology, Institute of Basic Health Sciences Universidade Federal Do Rio Grande Do Sul Porto Alegre RS Brazil
2 shared publications - A.B.T da Silveira
Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Brasil
1 shared publication - Alexandre Kleber Silveira
Universidade Federal do Rio Grande do Sul, Brasil
1 shared publication - Ana Helena Paz
Hospital de Clínicas de Porto Alegre
1 shared publication - Anelise Bergmann Araújo
Hospital de Clínicas de Porto Alegre
1 shared publication - Charles Francisco Ferreira
Universidade Federal do Rio Grande do Sul
1 shared publication
Latest Publications
- Open Access
- 8 May 2026
- Published by Wiley in Experimental Dermatology
- Vol. 35 (5) , e70264
A Phase II Trial of Perioperative Oral Itraconazole for the Management of Low‐Risk Basal Cell Carcinoma
Recently, new treatment strategies have been developed for advanced or metastatic basal cell carcinoma (BCC), including Hedgehog pathway inhibitors. Itraconazole has demonstrated clinical activity in such cases by blocking the smoothened (SMO) receptor. Such a strategy could be used in early disease. The objective of this Phase II study was to evaluate the clinical and molecular efficacy of Itraconazole in low‐risk BCC patients who were primarily candidates for surgical excision. Lesions were assessed according to RECIST 1.1 criteria, with target lesions being at least 10 mm in size after confirmatory biopsy. Patients received itraconazole tablets 200 mg twice daily for 60 days before resection. The median tumour diameter before treatment was 14 mm (IQR 11–16 mm), and after treatment, 13 mm (IQR 11–15 mm), and this reduction in tumour size was statistically significant ( p < 0.0001). Coupled with the decrease in tumour size, a decrease in the expression of CD105, an endothelial marker ( p < 0.0001), was observed. In conclusion, neoadjuvant itraconazole for 2 months was able to reduce the diameter of low‐risk BCC, and the effect was associated with a decrease in tumour angiogenesis and a favourable safety profile.
- 8 May 2026
- Published by Wiley in Experimental Dermatology
- Vol. 35 (5) , e70264
Open AccessA Phase II Trial of Perioperative Oral Itraconazole for the Management of Low‐Risk Basal Cell Carcinoma
Recently, new treatment strategies have been developed for advanced or metastatic basal cell carcinoma (BCC), including Hedgehog pathway inhibitors. Itraconazole has demonstrated clinical activity in such cases by blocking the smoothened (SMO) receptor. Such a strategy could be used in early disease. The objective of this Phase II study was to evaluate the clinical and molecular efficacy of Itraconazole in low‐risk BCC patients who were primarily candidates for surgical excision. Lesions were assessed according to RECIST 1.1 criteria, with target lesions being at least 10 mm in size after confirmatory biopsy. Patients received itraconazole tablets 200 mg twice daily for 60 days before resection. The median tumour diameter before treatment was 14 mm (IQR 11–16 mm), and after treatment, 13 mm (IQR 11–15 mm), and this reduction in tumour size was statistically significant ( p < 0.0001). Coupled with the decrease in tumour size, a decrease in the expression of CD105, an endothelial marker ( p < 0.0001), was observed. In conclusion, neoadjuvant itraconazole for 2 months was able to reduce the diameter of low‐risk BCC, and the effect was associated with a decrease in tumour angiogenesis and a favourable safety profile.
- Open Access
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 57, e13286
Guarana (Paullinia cupana) as a potential tool for mesenchymal stromal cells priming in regenerative medicine
Mesenchymal stromal cells (MSCs) have therapeutic potential due to their abilities of differentiation, immunomodulation, and migration to injured tissues, potentiating such effects when cells are activated. Guarana (Paullinia cupana) is a tropical plant species found in South America that is known for its antioxidant, stimulant, and cicatricial effects. The guarana extract is composed of many substances and caffeine is the main component. The objective was to evaluate the effects of guarana and caffeine on MSCs. After the initial characterization, MSCs were treated with Paullinia cupana (10, 100, and 1000 μg/mL) or caffeine (0.4, 4, and 40 μg/mL) for 24 h. MSCs treatment with 1000 μg/mL guarana increased cell polarity, viability, cell migration to chemoattractant, antioxidant potential, and liberation of extracellular vesicles (EVs), while it reduced the levels of autophagy. MSCs treated with 100 and 1000 μg/mL guarana or 40 μg/mL caffeine showed a decrease of cell proliferation. No treatment affected the cellular area and cell cycle of MSCs. The study shows in vitro evidence that guarana could be a promising alternative for activating MSCs to promote better cellular products for future clinical therapies.
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 57, e13286
Open AccessGuarana (Paullinia cupana) as a potential tool for mesenchymal stromal cells priming in regenerative medicine
Mesenchymal stromal cells (MSCs) have therapeutic potential due to their abilities of differentiation, immunomodulation, and migration to injured tissues, potentiating such effects when cells are activated. Guarana (Paullinia cupana) is a tropical plant species found in South America that is known for its antioxidant, stimulant, and cicatricial effects. The guarana extract is composed of many substances and caffeine is the main component. The objective was to evaluate the effects of guarana and caffeine on MSCs. After the initial characterization, MSCs were treated with Paullinia cupana (10, 100, and 1000 μg/mL) or caffeine (0.4, 4, and 40 μg/mL) for 24 h. MSCs treatment with 1000 μg/mL guarana increased cell polarity, viability, cell migration to chemoattractant, antioxidant potential, and liberation of extracellular vesicles (EVs), while it reduced the levels of autophagy. MSCs treated with 100 and 1000 μg/mL guarana or 40 μg/mL caffeine showed a decrease of cell proliferation. No treatment affected the cellular area and cell cycle of MSCs. The study shows in vitro evidence that guarana could be a promising alternative for activating MSCs to promote better cellular products for future clinical therapies.